What is the recommended treatment for osteoporosis?

Osteoporosis Treatment

For women with known osteoporosis, initiate pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce hip and vertebral fractures, and treat for 5 years. 1

First-Line Treatment for Women with Osteoporosis

Oral bisphosphonates (alendronate or risedronate) are the preferred first-line agents based on strong evidence for fracture reduction, favorable safety profile, and cost-effectiveness. 1 These medications reduce:

• Vertebral fractures by 50-70% 2
• Non-vertebral fractures by 20-30% 2
• Hip fractures by approximately 40% 2

Alternative first-line options when oral bisphosphonates are inappropriate include:

• Zoledronic acid (IV bisphosphonate): 5 mg annually, preferred if concerns about absorption or adherence 1
• Denosumab: 60 mg subcutaneously every 6 months, particularly for high fracture risk patients 1

Treatment for Men with Osteoporosis

Offer bisphosphonates to men with clinically recognized osteoporosis to reduce vertebral fractures. 1 The evidence is less robust than for women, but bisphosphonates remain the recommended first-line therapy. 1

Anabolic Therapy for Very High-Risk Patients

Consider anabolic agents (teriparatide, abaloparatide, or romosozumab) as initial therapy for patients at very high fracture risk, including those with:

• Recent vertebral fractures 3
• Hip fracture with T-score ≤-2.5 3
• Multiple fractures 3

Anabolic agents demonstrate superior anti-fracture efficacy compared to anti-resorptives in head-to-head studies and produce larger BMD increases. 2 However, anabolic therapy must be followed by anti-resorptive treatment to maintain fracture risk reduction, as their effects are transient. 2, 4

Treatment Duration and Monitoring

Treat for 5 years initially, then reassess risks and benefits for continuation. 1 Key considerations:

• Do not monitor BMD during the initial 5-year treatment period - fracture reduction occurs regardless of BMD changes. 1
• After 5 years of oral bisphosphonates, consider a drug holiday of 1-2 years to minimize atypical femoral fracture risk, particularly in lower-risk patients. 2
• For patients at moderate-to-high fracture risk after 5 years, continue active treatment rather than stopping. 1

Critical Pitfall: Denosumab Discontinuation

Never abruptly discontinue denosumab without transitioning to another anti-resorptive - there is pronounced loss of effect from 7 months after the last injection, which can result in clusters of rebound vertebral fractures. 2

Agents to Avoid

Do not use menopausal estrogen therapy, estrogen plus progestogen therapy, or raloxifene for osteoporosis treatment. 1 These agents carry significant cardiovascular risks including:

• Thromboembolic events 1
• Pulmonary embolism 1
• Cerebrovascular events 1

Adjunctive Therapy

All patients should receive:

• Calcium: 1,000-1,200 mg daily 1
• Vitamin D: 600-800 IU daily (800 IU for those ≥71 years) 1
• Weight-bearing and resistance training exercises 3, 5
• Fall prevention strategies 3, 5
• Smoking cessation and alcohol limitation (≤1-2 drinks/day) 1, 3

Treatment Selection Algorithm

For standard-risk osteoporosis:

1. Start with generic oral bisphosphonate (alendronate or risedronate) 1
2. If oral bisphosphonates contraindicated or not tolerated → IV zoledronic acid 1
3. If bisphosphonates inappropriate → denosumab 1

For very high-risk osteoporosis (recent fracture, multiple fractures, T-score ≤-3.0):

1. Consider anabolic agent first (teriparatide, abaloparatide, or romosozumab) 3, 2
2. Mandatory transition to anti-resorptive after anabolic therapy 2, 4

Common Adverse Effects to Counsel Patients About

Bisphosphonates:

• Mild upper GI symptoms (common) 1
• Atypical subtrochanteric fractures (rare, with long-term use) 1
• Osteonecrosis of the jaw (rare) 1

Denosumab:

• Mild upper GI symptoms 1
• Rash/eczema 1
• Rebound vertebral fractures if discontinued without transition 2

Zoledronic acid:

• Influenza-like symptoms (common with first infusion) 1
• Hypocalcemia 1
• Atrial fibrillation 1